10579

524404

MARKSANS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

MARKSANS PHARMA LIMITED Share Price Today

MARKSANS PHARMA LIMITED is currently trading at ₹256.07, down by ₹6.94 from the previous close. The stock touched an intraday high of ₹265.85 and a low of ₹253.60 during the latest trading session. Over the past one year, MARKSANS PHARMA LIMITED has delivered a return of 3.67%, while the stock has gained 16.25% in the last one month.

MARKSANS PHARMA LIMITED performance

Today’s low Today’s high
₹ 253.60 ₹ 265.85
₹ 256.07
52 week low 52 week high
₹ 155.00 ₹ 275.50
₹ 256.07
Open Price ₹ 264.80
Prev. Close ₹ 263.02
Volume (Shares) 1423556.00
Total traded value ₹ 3645.29
Upper Circuit ₹ 315.62
Lower Circuit ₹ 210.42
info

Investment Returns

Over 1 Month 16.25% Over 3 Months 55.00% Over 6 Months 43.08% Over 1 Year 3.67%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

MARKSANS PHARMA LIMITED fundamentals


  • Market cap (Cr) 11,604.20
  • P/E Ratio (TTM) 38.57
  • Beta 1.12
  • Book Value / share 36.46
  • Return on equity 14.45%
  • EPS (TTM) 6.64
  • Dividend yield 0.35%
  • Net profit/quarter (Cr) 91.92
info icon alternate text
  • Market cap (Cr) 11,605.50
  • P/E Ratio (TTM) 38.57
  • Beta 0.99
  • Book Value / share 36.46
  • Return on equity 14.45%
  • EPS (TTM) 6.64
  • Dividend yield 0.35%
  • Net profit/quarter (Cr) 91.92
info icon alternate text

MARKSANS PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 361.57
Operating Expense 264.69
Net Profit 91.92
Net Profit Margin (%) 25.42
Earnings Per Share (EPS) 2.03
EBITDA 133.47
Effective Tax Rate (%) 26.08
Particulars DEC 2025 (Values in Cr)
Revenue 339.73
Operating Expense 273.47
Net Profit 60.91
Net Profit Margin (%) 17.92
Earnings Per Share (EPS) 1.34
EBITDA 91.31
Effective Tax Rate (%) 25.81
Particulars SEP 2025 (Values in Cr)
Revenue 320.44
Operating Expense 257.14
Net Profit 99.81
Net Profit Margin (%) 31.14
Earnings Per Share (EPS) 2.20
EBITDA 130.26
Effective Tax Rate (%) 17.85
Particulars JUN 2025 (Values in Cr)
Revenue 319.73
Operating Expense 258.17
Net Profit 48.06
Net Profit Margin (%) 15.03
Earnings Per Share (EPS) 1.06
EBITDA 72.06
Effective Tax Rate (%) 24.41
Particulars MAR 2025 (Values in Cr)
Revenue 299.36
Operating Expense 256.09
Net Profit 37.59
Net Profit Margin (%) 12.55
Earnings Per Share (EPS) 0.83
EBITDA 58.39
Effective Tax Rate (%) 24.66
Particulars MAR 2026 (Values in Cr)
Revenue 1341.48
Operating Expense 1053.47
Net Profit 300.70
Net Profit Margin (%) 22.41
Earnings Per Share (EPS) 6.64
EBITDA 427.10
Effective Tax Rate (%) 23.20
Particulars MAR 2025 (Values in Cr)
Revenue 1174.37
Operating Expense 996.90
Net Profit 188.27
Net Profit Margin (%) 16.03
Earnings Per Share (EPS) 4.15
EBITDA 273.88
Effective Tax Rate (%) 22.60
Particulars MAR 2024 (Values in Cr)
Revenue 853.27
Operating Expense 743.46
Net Profit 133.76
Net Profit Margin (%) 15.67
Earnings Per Share (EPS) 2.95
EBITDA 202.01
Effective Tax Rate (%) 22.18
Particulars MAR 2023 (Values in Cr)
Revenue 655.20
Operating Expense 583.65
Net Profit 102.87
Net Profit Margin (%) 15.70
Earnings Per Share (EPS) 2.48
EBITDA 152.39
Effective Tax Rate (%) 22.09
Particulars MAR 2022 (Values in Cr)
Revenue 658.29
Operating Expense 566.04
Net Profit 103.99
Net Profit Margin (%) 15.79
Earnings Per Share (EPS) 2.54
EBITDA 155.97
Effective Tax Rate (%) 22.68
Particulars MAR 2025 (Values in Cr)
Book Value / Share 54.44
ROE % 16.89
ROCE % 20.19
Total Debt to Total Equity 0.12
EBITDA Margin 22.84
Particulars MAR 2024 (Values in Cr)
Book Value / Share 45.57
ROE % 16.53
ROCE % 20.78
Total Debt to Total Equity 0.10
EBITDA Margin 23.38
Particulars MAR 2023 (Values in Cr)
Book Value / Share 38.51
ROE % 18.00
ROCE % 21.77
Total Debt to Total Equity 0.08
EBITDA Margin 21.52
Particulars MAR 2022 (Values in Cr)
Book Value / Share 27.10
ROE % 17.89
ROCE % 22.83
Total Debt to Total Equity 0.07
EBITDA Margin 20.17
Particulars MAR 2021 (Values in Cr)
Book Value / Share 21.66
ROE % 31.34
ROCE % 38.77
Total Debt to Total Equity 0.04
EBITDA Margin 25.16
Particulars MAR 2025 (Values in Cr)
Book Value / Share 30.53
ROE % 14.45
ROCE % 18.55
Total Debt to Total Equity 0.01
EBITDA Margin 23.32
Particulars MAR 2024 (Values in Cr)
Book Value / Share 26.98
ROE % 11.46
ROCE % 14.67
Total Debt to Total Equity 0.01
EBITDA Margin 23.67
Particulars MAR 2023 (Values in Cr)
Book Value / Share 24.52
ROE % 10.85
ROCE % 14.11
Total Debt to Total Equity 0.01
EBITDA Margin 23.26
Particulars MAR 2022 (Values in Cr)
Book Value / Share 16.90
ROE % 15.02
ROCE % 19.45
Total Debt to Total Equity 0.02
EBITDA Margin 23.69
Particulars MAR 2021 (Values in Cr)
Book Value / Share 14.65
ROE % 17.29
ROCE % 22.04
Total Debt to Total Equity 0.02
EBITDA Margin 24.16
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 704.20
Total Assets 3239.63
Total Liabilities 3239.63
Total Equity 2489.38
Share Outstanding 45
Price to Book Ratio 7.28
Return on Assets (%) 11.74
Return on Capital (%) 15.15
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 673.57
Total Assets 2680.95
Total Liabilities 2680.95
Total Equity 2085.90
Share Outstanding 45
Price to Book Ratio 5.62
Return on Assets (%) 11.70
Return on Capital (%) 14.83
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 714.96
Total Assets 2190.38
Total Liabilities 2190.38
Total Equity 1765.07
Share Outstanding 45
Price to Book Ratio 2.87
Return on Assets (%) 12.15
Return on Capital (%) 14.74
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 349.26
Total Assets 1640.10
Total Liabilities 1640.10
Total Equity 1222.97
Share Outstanding 40
Price to Book Ratio 2.70
Return on Assets (%) 11.25
Return on Capital (%) 14.6
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 212.18
Total Assets 1228.81
Total Liabilities 1228.81
Total Equity 905.35
Share Outstanding 40
Price to Book Ratio 3.41
Return on Assets (%) 19.20
Return on Capital (%) 25.53
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 268.69
Total Assets 1755.30
Total Liabilities 1755.30
Total Equity 1383.48
Share Outstanding 45
Price to Book Ratio 7.28
Return on Assets (%) 10.72
Return on Capital (%) 13.61
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 312.22
Total Assets 1516.03
Total Liabilities 1516.03
Total Equity 1222.70
Share Outstanding 45
Price to Book Ratio 5.62
Return on Assets (%) 8.82
Return on Capital (%) 10.94
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 440.26
Total Assets 1344.86
Total Liabilities 1344.86
Total Equity 1111.32
Share Outstanding 45
Price to Book Ratio 2.87
Return on Assets (%) 7.64
Return on Capital (%) 9.26
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 224.04
Total Assets 965.60
Total Liabilities 965.60
Total Equity 784.67
Share Outstanding 40
Price to Book Ratio 2.70
Return on Assets (%) 10.76
Return on Capital (%) 13.17
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 105.61
Total Assets 740.69
Total Liabilities 740.69
Total Equity 599.71
Share Outstanding 40
Price to Book Ratio 3.41
Return on Assets (%) 13.28
Return on Capital (%) 16.4
Particulars MAR 2025 (Values in Cr)
Net Income 503.96
Cash from Operations 332.56
Cash from Investing -49.00
Cash from Financing -65.14
Net change in Cash 92.50
Free Cash Flow 505.48
Particulars MAR 2024 (Values in Cr)
Net Income 423.52
Cash from Operations 352.75
Cash from Investing -140.84
Cash from Financing -68.72
Net change in Cash 20.84
Free Cash Flow 561.59
Particulars MAR 2023 (Values in Cr)
Net Income 337.65
Cash from Operations 300.42
Cash from Investing -259.21
Cash from Financing 197.82
Net change in Cash 176.02
Free Cash Flow 354.05
Particulars MAR 2022 (Values in Cr)
Net Income 247.51
Cash from Operations 172.11
Cash from Investing -84.39
Cash from Financing 79.51
Net change in Cash 94.37
Free Cash Flow 218.44
Particulars MAR 2021 (Values in Cr)
Net Income 302.16
Cash from Operations 227.12
Cash from Investing -44.84
Cash from Financing -15.28
Net change in Cash 118.45
Free Cash Flow 273.54
Particulars MAR 2025 (Values in Cr)
Net Income 243.25
Cash from Operations 77.55
Cash from Investing 17.24
Cash from Financing -29.91
Net change in Cash 18.33
Free Cash Flow 197.46
Particulars MAR 2024 (Values in Cr)
Net Income 171.89
Cash from Operations 72.81
Cash from Investing -114.22
Cash from Financing -26.21
Net change in Cash -106.38
Free Cash Flow 228.48
Particulars MAR 2023 (Values in Cr)
Net Income 132.03
Cash from Operations 83.34
Cash from Investing -194.62
Cash from Financing 210.01
Net change in Cash 67.12
Free Cash Flow 118.62
Particulars MAR 2022 (Values in Cr)
Net Income 134.50
Cash from Operations 87.80
Cash from Investing -128.06
Cash from Financing 70.86
Net change in Cash -1.23
Free Cash Flow 110.65
Particulars MAR 2021 (Values in Cr)
Net Income 124.33
Cash from Operations 127.13
Cash from Investing 8.87
Cash from Financing -13.53
Net change in Cash 102.26
Free Cash Flow 148.13
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.51 13.02 1.52 241.47 23.12 38.85
BLISS GVS PHARMA LTD 492.50 39.98 4.37 5223.27 118.35 495.00
CIPLA LTD. 1440.30 30.57 3.37 116353.96 1165.55 1672.20
FERMENTA BIOTECH LTD. 365.50 16.12 2.64 1075.70 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.51 22.03 4.05 241.47 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 538.05 24.12 4.20 1555.54 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8382.65 109.48 24.01 20956.63 7630.00 9850.00
BLISS GVS PHARMA LTD 492.50 53.13 4.52 5223.27 118.35 495.00

MARKSANS PHARMA LIMITED shareholding pattern

Holding
32.78%
43.87%
16.76%
6.57%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

MARKSANS PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
256.07 -2.64 redarrow
red-green-graph indicator
4 Bearish
12 Bullish
  • 5 Days 259.00
  • 26 Days 243.10
  • 10 Days 256.20
  • 50 Days 226.30
  • 12 Days 254.80
  • 100 Days 209.10
  • 20 Days 248.20
  • 200 Days 203.00
266.54 PIVOT
First Support 257.58 First Resistance 271.98 Second Support 252.14 Second Resistance 280.94 Third Support 243.18 Third Resistance 286.38
RSI 59.86 ADX 37.81 MACD 11.62 Williams % R -41.08 Commodity Channel Index (CCI) 75.57
Date 2026-06-25 Week 1032899.00 Same Day 627372.00 Month 1194128.00
1 Year 1.12 3 Year 1.11
Over 1 Month
16.25% down
Over 1 Year
3.67% down
Over 3 Months
55.00% down
Over 3 Years
41.15% down
Over 6 Months
43.08% down
Over 5 Years
24.05% down

MARKSANS PHARMA LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
01 Aug 2025 0.8 Final 01 Aug 2025 Equity shares
17 Sep 2024 0.6 Final 17 Sep 2024 Equity shares
07 Jun 2023 0.5 Final 07 Jun 2023 Equity shares
19 Aug 2022 0.25 Final 23 Aug 2022 Equity shares
15 Sep 2021 0.25 Final 17 Sep 2021 Equity shares
22 Sep 2020 0.1 Final 24 Sep 2020 Equity shares
19 Sep 2019 0.05 Final 21 Sep 2019 Equity shares
19 Sep 2018 0.05 Final 22 Sep 2018 Equity shares
19 Sep 2017 0.05 Final 21 Sep 2017 Equity shares
22 Sep 2016 0.12 Final 24 Sep 2016 Equity shares
23 Sep 2015 0.12 Final 26 Sep 2015 Equity shares
18 Sep 2014 0.1 Final 20 Sep 2014 Equity shares
Ex-Date Old FV NEW FV Record Date
11 Mar 2008 10.0 1.0 18 Mar 2008
Dividend date Dividend amount Dividend type Record date Instrument type
01 Aug 2025 0.8 Final 01 Aug 2025 Equity shares
17 Sep 2024 0.6 Final 17 Sep 2024 Equity shares
07 Jun 2023 0.5 Final 07 Jun 2023 Equity shares
19 Aug 2022 0.25 Final 23 Aug 2022 Equity shares
15 Sep 2021 0.25 Final 17 Sep 2021 Equity shares
22 Sep 2020 0.1 Final 24 Sep 2020 Equity shares
19 Sep 2019 0.05 Final 21 Sep 2019 Equity shares
19 Sep 2018 0.05 Final 22 Sep 2018 Equity shares
19 Sep 2017 0.05 Final 21 Sep 2017 Equity shares
22 Sep 2016 0.12 Final 24 Sep 2016 Equity shares
23 Sep 2015 0.12 Final 26 Sep 2015 Equity shares
18 Sep 2014 0.1 Final 20 Sep 2014 Equity shares
Ex-Date Old FV NEW FV Record Date
11 Mar 2008 10.0 1.0 18 Mar 2008

Top Gainers

Top Losers

Marksans Pharma Share Result Highlights

Particulars

Sep 2024 (₹ in Cr)

Jun 2024 (₹ in Cr)

Mar 2024 (₹ in Cr)

Dec 2023 (₹ in Cr)

Sep 2023 (₹ in Cr)

Revenue

308.63

254.53

225.20

241.36

204.67

Operating Expense

263.65

220.38

198.98

208.09

176.10

Net Profit

63.20

32.02

32.99

25.29

31.29

Net Profit Margin (%)

20.47

12.58

14.64

10.47

15.28

Earnings Per Share (₹)

1.39

0.71

0.73

0.56

0.69

EBITDA

83.64

49.42

46.09

43.30

53.23

Effective Tax Rate (%)

17.19

24.30

14.08

26.90

29.68

Key Highlights:

  • Revenue Growth: Revenue grew significantly in Sep 2024 to ₹308.63 Cr from ₹204.67 Cr in Sep 2023.
  • Strong Profit Performance: Net profit increased to ₹63.20 Cr with a 20.47% margin.
  • Earnings Per Share (EPS): The EPS surged to ₹1.39 in Sep 2024.
  • Operating Efficiency: Operating expenses grew slower than revenue, improving margins.
  • The Marksans Pharma share price has shown positive results, reflecting the growth in key financial metrics.

Marksans Pharma Share Annual Reports

Particulars

Mar 2024 (₹ in Cr)

Mar 2023 (₹ in Cr)

Revenue

853.27

732.00

Operating Expense

743.46

650.23

Net Profit

133.76

112.65

Net Profit Margin (%)

15.67

15.39

Earnings Per Share (₹)

2.95

2.50

EBITDA

202.01

180.52

Effective Tax Rate (%)

22.18

20.50

Key Highlights:

  • Revenue Growth: Revenue increased by approximately ₹121.27 Cr from ₹732.00 Cr in FY 2022-23.
  • Profitability: The net profit grew to ₹133.76 Cr in FY 2023-24 with a 15.67% margin.
  • Strong EPS Performance: Earnings per share rose to ₹2.95.
  • Operational Efficiency: EBITDA grew by ₹21.49 Cr, reflecting improved operational efficiency.
  • The annual financial performance has had a positive impact on the Marksans Pharma share price, reflecting steady growth in revenue and profits.

Marksans Pharma Share Dividend

Particulars

Ex-Date

Record Date

Dividend per Share (₹)

07 Jun, 2023

07 Jun, 2023

Dividend Yield (%)

0.5

Equity Shares

Key Highlights:

  • Consistent Payouts: Marksans Pharma has regularly paid dividends, with the latest payout of ₹0.5 per share in June 2023.
  • Shareholder Returns: Dividend yields have been consistent, offering moderate returns to shareholders.
  • Final Dividends: Recent payouts have been final dividends, reflecting the company’s strong profit performance.
  • The dividend payouts complement the overall performance of the Marksans Pharma share price, providing additional value to investors.

Popular FAQs

Who is the CEO of Marksans Pharma Ltd?

Marksans Pharma Ltd is led by Mr. Mark Saldanha, who serves as the Managing Director and Chief Executive Officer of the company. Under his leadership, the company has expanded its presence in the global pharmaceutical market and achieved significant growth in various regions. Mr. Saldanha’s vision has been instrumental in driving the company’s strategic acquisitions, as well as in its research and development initiatives.

 

When was Marksans Pharma established?

Marksans Pharma Ltd was initially incorporated as Tasc Pharmaceuticals Limited in April 1982. Following a Scheme of Amalgamation, the company’s name was changed to Marksans Pharma Ltd on 10th October 2005. The rebranding marked the beginning of the company’s expanded focus on pharmaceutical formulations, and since then, it has become a prominent player in the pharmaceutical sector.

 

What factors influence the Marksans Pharma Share Price?

The Marksans Pharma share price is influenced by several key factors, including:

  • The company’s financial performance, including revenue growth, net profit, and earnings per share (EPS)
  • Acquisitions and R&D activities
  • Strong revenue and profit growth that boosts investor confidence
  • Successful product launches and US FDA approvals
  • Expanding R&D facilities
  • Broader pharmaceutical market trends and regulatory changes
  • Global economic factors impacting stock performance

 

Is Marksans Pharma debt-free?

Marksans Pharma Ltd is not entirely debt-free. However, the company has maintained a manageable level of debt as part of its capital structure. It strategically acquires businesses and invests in research and development to fuel its growth. The debt levels are often monitored to ensure they do not adversely impact the company's financial health. Despite this, the company has successfully maintained profitability and strong cash flow, helping it manage its liabilities efficiently.

 

What is the CAGR of Marksans Pharma Share?

The Marksans Pharma share price has demonstrated a Compound Annual Growth Rate (CAGR) of:

  • 20% over the last 10 years
  • 87% over the last 5 years
  • 72% over the last 3 years
  • 96% over the past year

This impressive growth rate highlights the company’s consistent performance and the market’s positive response to its strategic initiatives, including acquisitions and expanding its product portfolio.

 

How has the Marksans Pharma Share Price performed over the past year?

Over the past year, the Marksans Pharma share price has seen a remarkable increase of 96%. This surge in share price reflects strong financial performance, successful product approvals, and the company's continued expansion in both domestic and international markets. The robust growth in the past year has also been fueled by investor confidence, supported by strategic acquisitions such as Tevapharm India and the company's increasing presence in the global pharmaceutical industry.

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Marksans Pharma Ltd?

Answer Field

Marksans Pharma Ltd share price is for NSE ₹ 256.07 & for BSE ₹ 256.10 as on Jun 25 2026 03:30 PM.

What is the Market Cap of Marksans Pharma Ltd Share?

Answer Field

The market cap of Marksans Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 25 2026 03:30 PM.

What is the 52 Week High and Low of Marksans Pharma Ltd?

Answer Field

The 52 Week High and Low of Marksans Pharma Ltd for NSE is ₹ 275.50 and ₹ 155.00 and for BSE is ₹ 275.25 and ₹ 156.00.

What is 1 year return for Marksans Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 3.67%.

What is the P/E Ratio of Marksans Pharma Ltd Share?

Answer Field

As on Jun 25 2026 03:30 PM the price-to-earnings (PE) ratio for Marksans Pharma Ltd share is 38.57.

What is the PB ratio of Marksans Pharma Ltd Share?

Answer Field

As on Jun 25 2026 03:30 PM, the price-to-book (PB) ratio for Marksans Pharma Ltd share is 36.46.

How to Buy Marksans Pharma Ltd Share?

Answer Field

You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Marksans Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Marksans Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Marksans Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Marksans Pharma Ltd?

Answer Field

Marksans Pharma Ltd is led by Mr. Mark Saldanha, who serves as the Managing Director and Chief Executive Officer of the company. Under his leadership, the company has expanded its presence in the global pharmaceutical market and achieved significant growth in various regions. Mr. Saldanha’s vision has been instrumental in driving the company’s strategic acquisitions, as well as in its research and development initiatives.

When was Marksans Pharma established?

Answer Field

Marksans Pharma Ltd was initially incorporated as Tasc Pharmaceuticals Limited in April 1982. Following a Scheme of Amalgamation, the company’s name was changed to Marksans Pharma Ltd on 10th October 2005. The rebranding marked the beginning of the company’s expanded focus on pharmaceutical formulations, and since then, it has become a prominent player in the pharmaceutical sector.

What factors influence the Marksans Pharma Share Price?

Answer Field

The Marksans Pharma share price is influenced by several key factors, including:

  • The company’s financial performance, including revenue growth, net profit, and earnings per share (EPS)
  • Acquisitions and R&D activities
  • Strong revenue and profit growth that boosts investor confidence
  • Successful product launches and US FDA approvals
  • Expanding R&D facilities
  • Broader pharmaceutical market trends and regulatory changes
  • Global economic factors impacting stock performance

Is Marksans Pharma debt-free?

Answer Field

Marksans Pharma Ltd is not entirely debt-free. However, the company has maintained a manageable level of debt as part of its capital structure. It strategically acquires businesses and invests in research and development to fuel its growth. The debt levels are often monitored to ensure they do not adversely impact the company's financial health. Despite this, the company has successfully maintained profitability and strong cash flow, helping it manage its liabilities efficiently.

What is the CAGR of Marksans Pharma Share?

Answer Field

The Marksans Pharma share price has demonstrated a Compound Annual Growth Rate (CAGR) of:

  • 20% over the last 10 years
  • 87% over the last 5 years
  • 72% over the last 3 years
  • 96% over the past year

This impressive growth rate highlights the company’s consistent performance and the market’s positive response to its strategic initiatives, including acquisitions and expanding its product portfolio.

How has the Marksans Pharma Share Price performed over the past year?

Answer Field

Over the past year, the Marksans Pharma share price has seen a remarkable increase of 96%. This surge in share price reflects strong financial performance, successful product approvals, and the company's continued expansion in both domestic and international markets. The robust growth in the past year has also been fueled by investor confidence, supported by strategic acquisitions such as Tevapharm India and the company's increasing presence in the global pharmaceutical industry.

No results found

close-image
Get Free Demat Account*
+91
close-img
Authorise with OTP
Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|